Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

General Information

Summary This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML). The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Clinical trials phase Phase 1
Start date (estimated) 2022-10-28
End date (estimated) 2025-10-21
Clinical feature
Label acute myeloid leukemia
Description A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT05601466
ICTRP weblink
Other study identifiers
Name QN023aTXM1
Source weblink https:/
Public contact
Public email
First name Jiangxing
Last name Wang
Phone +86-22-23909120
City Tianjin
Sponsors Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin, China


Which differentiated cell type is used
Label natural killer cell
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 18